Matches in Wikidata for { <http://www.wikidata.org/entity/Q91999522> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q91999522 description "artículu científicu espublizáu n'avientu de 2019" @default.
- Q91999522 description "im Dezember 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91999522 description "scientific article published on 16 December 2019" @default.
- Q91999522 description "wetenschappelijk artikel" @default.
- Q91999522 description "наукова стаття, опублікована 16 грудня 2019" @default.
- Q91999522 name "First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis" @default.
- Q91999522 name "First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis" @default.
- Q91999522 type Item @default.
- Q91999522 label "First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis" @default.
- Q91999522 label "First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis" @default.
- Q91999522 prefLabel "First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis" @default.
- Q91999522 prefLabel "First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis" @default.
- Q91999522 P1433 Q91999522-18D9A533-F641-4B1F-BD56-75BAD9DD2671 @default.
- Q91999522 P1476 Q91999522-223DB871-24BB-4A61-BFC8-F551BE5C8E0C @default.
- Q91999522 P2093 Q91999522-14D42C5C-F425-41C5-8ABD-122023D39642 @default.
- Q91999522 P2093 Q91999522-1CC3F641-1985-48CC-8994-326B4C4F587B @default.
- Q91999522 P2093 Q91999522-3AC54DDB-CA9C-476C-8269-17688A741257 @default.
- Q91999522 P2093 Q91999522-3FD9554C-AD8D-4626-BF12-9FE3A8D8D56B @default.
- Q91999522 P2093 Q91999522-4D48AE6C-AED0-48E5-8BCE-04FCAEFED551 @default.
- Q91999522 P2093 Q91999522-6D121962-92BF-4B5A-8519-841D0F79CAA4 @default.
- Q91999522 P2093 Q91999522-99404B3C-5A2D-4CE3-9820-F0E41ACE22FA @default.
- Q91999522 P2093 Q91999522-B41A4201-37F7-4FD3-99F1-5647C121C5CC @default.
- Q91999522 P2093 Q91999522-DF1A6FA7-2657-4170-8123-D08CC69325DE @default.
- Q91999522 P31 Q91999522-6BAC4B60-3159-4F56-A787-85FE89F8262F @default.
- Q91999522 P356 Q91999522-32EBFDA1-FFF6-4338-918D-7DAC0B062D95 @default.
- Q91999522 P50 Q91999522-809AA9E5-4CF6-4486-B7FE-690D12FED04F @default.
- Q91999522 P50 Q91999522-B7AD4B95-07F5-42A6-84AE-36E48F2E49B7 @default.
- Q91999522 P577 Q91999522-8AD72647-FC14-447B-A6CB-844984DA919A @default.
- Q91999522 P698 Q91999522-9C9818BC-FE5A-43DD-A289-D2780CF7728D @default.
- Q91999522 P356 FON-2019-0578 @default.
- Q91999522 P698 31840537 @default.
- Q91999522 P1433 Q2781597 @default.
- Q91999522 P1476 "First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis" @default.
- Q91999522 P2093 "Aaron B Cohen" @default.
- Q91999522 P2093 "David J Vaughn" @default.
- Q91999522 P2093 "Emily K Feld" @default.
- Q91999522 P2093 "John P Christodouleas" @default.
- Q91999522 P2093 "Matthew D Galsky" @default.
- Q91999522 P2093 "Neal J Meropol" @default.
- Q91999522 P2093 "Ronac Mamtani" @default.
- Q91999522 P2093 "Shimon Ben Boursi" @default.
- Q91999522 P2093 "Shrujal S Baxi" @default.
- Q91999522 P31 Q13442814 @default.
- Q91999522 P356 "10.2217/FON-2019-0578" @default.
- Q91999522 P50 Q91999514 @default.
- Q91999522 P50 Q91999518 @default.
- Q91999522 P577 "2019-12-16T00:00:00Z" @default.
- Q91999522 P698 "31840537" @default.